Navigation Links
Viteava Pharmaceuticals Executes Worldwide Exclusive License
Date:11/19/2013

redient, EGCG, to design commercially-viable drug candidates."

Viteava Pharmaceuticals will focus on the development of novel approaches to manage cancer and related conditions. It has identified VPE001, a prodrug of EGCG with improved bioavailability and potency, as its lead drug candidate expected to enter clinical development in 2015. Initial clinical indications may include the treatment of uterine fibroids and/or delaying the progression of cancer in high-risk, early-stage chronic lymphocytic leukemia patients.

Professor Dou added, "My laboratory was the first to identify inhibition of proteasomal chymotrypsin-like activity as an important mechanism of action of EGCG. We also know that EGCG can also affect, albeit to a lesser extent, other important pathways, such as PI3K/Akt/mTOR signaling. Viteava's drug candidates target diseases where these pathways are dysregulated."

The company's strategy focuses principally on clinical indications where green tea extracts have been demonstrated to elicit biological responses in human studies. Viteava's drug candidates are designed to improve these treatment regimens and achieve better clinical outcomes, while retaining a high level of safety. By regulating multiple pathways important to the progression of diseases such as cancer, Viteava's drug candidates are expected to provide advantages over more potent and more selective drugs that usually only elicit temporary responses together with a high level of toxicity.

Robert Foldes added that "our strategy certainly reduces clinical development risk while targeting significant medical conditions lacking efficacious long-term pharmaceutical interventions and where we can significantly improve standard-of-care."

About Viteava Pharmaceuticals Inc.

Viteava is a start-up drug development company dedicated to improving the treatment and management of cancer and related conditions to enhance qualit
'/>"/>

SOURCE Viteava Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biotest Pharmaceuticals Honored with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for "Business Expansion"
2. GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
3. Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
4. Hi-Tech Pharmaceuticals Sues The FDA For "Bullying Tactics"
5. GW Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
6. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
7. RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
8. Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
9. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
10. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
11. ANI Pharmaceuticals To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
(Date:9/19/2014)... One of the major trends in the market ... useful in different application sectors such as hard tissue ... forecast the Global Bioactive Material Market to ... period 2013-2018. According to the report, increase in aging ... market. There will be an increased number of trauma, ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered ... Well-Being Coach Christi Hall to campus. , Hall’s journey to ... and gaining weight as a result of years of medication. ... about nutrition. One year later she had lost 50 pounds, ... endurance and cardio. , After joining the YMCA staff, she ...
(Date:9/19/2014)... There are thousands of older women who ... and there are thousands of younger men who would love ... SeekingCougar.com now provides the world's best collection of resources ... older women, and the younger men who would like to ... these people to meet each other and establish those romantic ...
(Date:9/18/2014)... Thompson and Mathieu Nikel decided it was time to tie the ... Isaac, said there was only one choice for them – Mercy ... Thompson was an undergraduate student and needed a French tutor. She ... French and so she asked him. , Thompson is ... was 7 years old. Nikel is originally from France came ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a ... of Facial Plastic and Reconstructive Surgery and a Professor ... Facial Plastic Surgery. He is recognized around the ... , Dr. Ellis will be presenting on numerous injectable ... injection techniques and various treatments for complications associated with ...
Breaking Medicine News(10 mins):Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 2Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 3Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 4Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2
... Oct. 17 Symmetry Medical Inc.,(NYSE: SMA ... global orthopedic,device industry and other medical markets, announced ... Officer, Europe effective November 1,2007. Mr. Hynes ... case facilities across Europe including the UK, Ireland,France ...
... against the facial paralysis, study finds , , WEDNESDAY, Oct. 17 ... at easing a form of facial paralysis called Bell,s palsy ... that acyclovir may not be a new, improved treatment option ... the other hand, many people afflicted with Bell,s palsy do ...
... receive failing grades , , WEDNESDAY, Oct. 17 (HealthDay News) -- ... to women,s health, a new report contends. , The report ... meets only three of 27 benchmarks for women,s health. Those ... who get regular mammograms; the percentage of women who visit ...
... Include New Research on HIV Screening, Pandemic Flu,Neonatal ... WASHINGTON, Oct. 17 More than 13,000 public,health ... to address the,nation,s top public health challenges at ... The conference will feature leading experts, researchers ...
... Oct. 17 Two health care leaders were,presented ... (MHA),Health Care Leadership Award. Terence F. Moore, president ... the award in the,category of hospital management and ... with the award in the category of patient ...
... Lumenos suite of products helps consumers manage costs and adopt healthier ... ... Anthem Blue Cross and Blue,Shield in Virginia is now offering new health ... about health,care-helping them to lead healthier lives and gain control over the ...
Cached Medicine News:Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:Antiviral Won't Improve Bell's Palsy Outcome 2Health News:U.S. Women's Health Care Still Falls Short: Report 2Health News:U.S. Women's Health Care Still Falls Short: Report 3Health News:Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting, Nov. 3-7 2Health News:Association Honors Health Care Leaders in Midland and Troy 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 3Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 4
... The Infinity AST (GOT) powder reagent ... convenience of single liquid stability to help ... provide quick result turnaround time. The patented ... reagent provides a long shelf life and ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: